Hester Biosciences Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Hester Biosciences’s Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Hester Biosciences Q3 Results 2026 Preview

• Hester Biosciences’s revenue is expected to be in the range of ₹1,049.82 crore, a 3.37% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 41.36% YoY. 
• Hester Biosciences’s EBITDA is expected to fall to ₹103.25 crore. 
• Net profit is ₹56.79 crore, a fall 41.36% YoY 

Hester Biosciences Share Performance 

• Over the past six months, Hester Biosciences’ share price has fallen by 8.95% to ₹538.65.
• Moreover, over the past year, the stock has increased by 12.87%.
• Despite this weak short-term performance, Hester Biosciences’ stock has delivered a financially sound 239.85% return over the past 5 years.
• As of 29th January 2026, the stock traded at ₹538.05 per share.

Key Factors to Watch for Hester Biosciences Q3 Results FY26 

• Revenue & Sales Growth: Watch overall topline trend and product revenue performance across vaccines, health products, and petcare.
• Profitability & Margins: Monitor EBITDA and PAT margins to see if cost management supports earnings.
• Divisional Performance: Track trends across the poultry healthcare, animal healthcare, and petcare segments, as different divisions can drive varying momentum.
• Government/Tender Impact: Look for commentary on government immunisation programs and institutional tenders (e.g., PPR, LSD) that can influence future sales.

Final Thoughts

Hester Biosciences will announce its Q3 FY26 results on 30th January 2026. Analysts expect 5.27% YoY revenue growth, a 0.95% fall in PAT, and a 5.99% fall in EBITDA. Hester Biosciences focuses on manufacturing and supplying a comprehensive range of animal healthcare solutions — primarily poultry and large‑animal vaccines, health products, diagnostics and related services — to prevent and manage diseases in livestock and poultry, while expanding its global presence in key markets.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here